• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. Its lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company is also developing CEL-1000, which is derived from a pre-clinical technology called ?Ligand Epitope Antigen Presentation System? to stimulate the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer; and CEL-2000 for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.

NO
     
CVM (CEL-SCI Corp)
Last Trade 13.94 Date 1/30/2020
Change % -1.70 % Price Change -0.24
Open 14.12 52 Week High 15.0
High 14.34 52 Week Low 2.3668
Low 13.71 Type stock
Volume 495612 Average Volume 690024
Prev Close 14.18 Stock Exchange A
Bid 13.9 Ask 13.96
Bid Size 2 Ask Size 1
1st Yr Estimated EPS Growth -0.1609 2nd Yr Estimated EPS Growth 0.1864
2 Years Forward Earning Yield -0.0494 2 Years Forward PE Ratio
2 Years EV/Forward EBIT -16.244 2 Years EV/Forward EBITDA -18.6328
Book Value per Share 0.1451 Book Value Yield 0.0102
Buy Back Yield 0.0 CAPE Ratio
Cash Return -0.0329 Cash Flow per Share -0.5235
Cash Flow Yield -0.0369 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.0501 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT -21.6586 EV / Forward EBITDA -24.9661
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue EV / Total Asset 18.3475
Expected Dividend Growth Rate Free Cash Flow per Share -0.5343
Free Caash Flow Ratio Free Cash Flow Yield -0.0377
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.0416 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 97.736811 PB Ratio 10 Year Growth 0.366408
PB Ratio 3 Year Growth 7638.541079 Cash Ratio 3 Year Average 2197.2544
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 1.549727
Price to Cash Ratio 59.415236 Price / EBITDA
Price to Sales Ratio Price to Sales Ratio 10 Year Growth
Price to Sales Ratio 3 Year Avg Price to Sales Ratio 5 Year Avg
Sale per Share 0.0 Sales Yield 0.0
Sustainable Growth Rate -8.6218 Tangible Book Value per Share 0.1363
Tangible Book Value per Share 3 year Avg -0.0471 Tangible Book Value per Share 5 year Avg -0.2722
Total Asset per Share 0.7807 Total Yield 0.0
Working Capital per Share 0.192 Working Capital per Share 3 Year Avg -0.0757
Working Capital per Share 5 Year Avg 0.0799 Beta 5.008543